http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Chong-pil (검색결과 203 건)
- 무료
- 기관 내 무료
- 유료
-
-
人蔘의 Oil중의 β-sitosterol의 確認 및 定量
安永弼,鄭鍾天 건국대학교 1970 學術誌 Vol.11 No.1
β-sitosterol was separated in korean panax ginseng by TLC and was identified by N.M.R. mass spectra, IR, and T.L.C. method Form our result, free campesterol and stigmasterol absent while contained only free β-sitosterol in ether extract fraction. The quantitative determination of the β-sitosterol was performed with colorimetry method. Average amount were 2.0mg-3.5mg per ten gram of ginseng powder.
-
3상 유도전동기 운전에 대한 고조파 위상각 영향의 분석
고성필,좌종근 제주대학교 공과대학 첨단기술연구소 2005 尖端技術硏究所論文集 Vol.16 No.2
This paper describes an analysis of the effect of low harmonic orders and phase angles on the operation performance of a three-phase induction motor. In the analysis, the voltage harmonic orders from 2 to 7, with the three different voltage distortion factors were chosen except the triple harmonics, and each harmonic order was designed into four kinds of waveforms whose phase angles are divided one cycle into four parts. The analyzed data includes current distortion factor, voltage form factor, current form factor, input voltage, input current, and efficiency. From the analyzed result, it is found that the operation performance of a three-phase induction motor does not vary by phase angle of each individual harmonic order. But both voltage and current form factors related to the waveforms are affected by the harmonic phase angle in odd harmonics.
-
李鍾弼 대구효성가톨릭대학교 1967 연구논문집 Vol.1967 No.2
The following results have been obtained in the sutdies of the relation between metabolism and formation of root knob in the cotyledon of green beans. 1. The formation of root knob was observed approximately threeweeks after germination in the young plant of green beans. 2. The formation of root knob was not affected by the removal of cotyledon in the early stages of development in the young plant of green beans. However, only a slight damage was observed in the over all developement of young plant of green beans.
-
Comparative double blind test에 의한 抗아메바劑 Ro7-0207(Tiberal), Metronidazole 및 Dehydroemetine의 治效成績의 比較
李午政,全鍾暉,朴弼遠,朴壽泳 대한감염학회 1974 감염 Vol.6 No.1
Introduction New and better substances are still being sought for the treatment of amoebiasis. The aim of this trial is to assess the effectiveness and tolerance of Tiberal and oral dehydroemetine in patients with oligosymptomatic (or mild) intestinal amoebiasis comparing with that of metronidazole which are known to be an active amoebicide. Selection of cases. Lately, classical symptomatic amoebiasis accompanying mucus-bloody stool and tenesmus could be seldom experienced at urban areas in this country. At here the majority of intestinal amebiasis is manifested by loose stools containing mucus, pus or blood (rare), and also by a rapid response to antibioties, but with frequent episods of recurrence caused by diet-failure or alcohol drinking. Among 187 cases of mild enterocolitis which were suspected as being mild intestinal amoebiasis clinically, authors selected amoeba-positive 60 cases and additional 7 cases which were included later in this clinical trial study. The 7 drop-outs in the original study were replaced by these additional 7 cases. The clinical trials were carried out at the St. Mary's Hospital, Catholic Medical College, Seoul, Republic of Korea. During 12 month (April 25, 1973-May 17, 1974), we treated 60 cases of so-called oligosymptomatic amoebiasis with above mentioned three amoebicides. 60 ambulatory cases suffering from mild GI troubles were admitted into the trial (liable to recurrent diarrhoeal stools including mucus, or pus with tenesmus, and also to lower abdominal discomfort of mild pain) those were suspected clinically as having intestinal amoebiasis with carriers of E. histolytica (trophozoits and/or cysts in the feces). Oligosymptomatic amoebiasis group, in this clinical trial study, consisted of 34 males and 26 females ranging from 17 to 62 years of age. All were adolescents or adults and their age distribution was shown in Table 1. Methodology on this clinical trials. We have carried out so-called the comparative double blind trials with Tiberal versus Metronidazole versus oral Dehydroemetine in symptomatic amoebiasis of mild grade. The trial drugs were given also without the knowledge of either the one who gave it or the one who got it in this comparative double blind study. Both (drug examiner) doctors and (drug examined) patients have had no knowledge of each drug. Pharmacist responded to doctor's prescription with code numbers. After the completion of the study the exact name of a drug were publically drawn from the code numbers and the purpose of double blind study was attained. In this study an arrangement for a drug administration schedule was set by as pharmacist exclusively. 60 patients were assigned to one of the three drugs by proper randomization so that 20 patients received tiberal and 20 metronidazole and 20 oral dehydroemetine. After the trial, code numbers of the drugs were identified; nos. 1, 6, 10, 14, 19, 23, 25, 27, 28, 29, 33, 34, 35, 36, 44, 45, 47, 51, 53, and 54 were tiberal; 8, 9, 11, 12, 13, 15, 16, 18, 20, 22, 32, 39, 41, 48, 49, 50, 52, 55, 56, and 57 were metronidazole, and nos. 2, 3, 4, 5, 7, 17, 21, 24, 26, 30, 31, 37, 38, 40, 42, 43, 46, 58, 59 and 60 were oral dehydroemetine. Evaluation The therapeutic effects were assessed by the clinical evolution and by stool parasitology (direct examination and concentration method) performed on day 3 and 6 on treatment, and then at the end of treatment (8-10 day) and one month after the initial treatment. This made a total 4 to 5 parasitological examination per patient, including one examination required for diagnosis prior to treatment. At the same time aspect and consistency of the stool were registered. The effect of the drugs on other protozoa found in the stools were also reported. The tolerance were assessed by clinical findings and laboratory studies made in limited cases at least before and after treatment unless otherwise stated. Blood count, BUN, Alkaline phosphatase, SGP, TECG and urinalysis were performed as laboratory controls. Authors have established following evaluation criteria for this clinical study. Radical cure: free of symptoms with no vegetative or cystic forms of E. histolytica in stool on 3 successive tests. Biological cure: no cystic forms of E. histolytica in stool on 3 successive tests, but persistence of some intestinal disturbances. Relapse: apparent cure or improvement (with negative of 3 successive tests) followed by recurrence with vegetative amoeba on direct smear within 30 days. (re-infection may be included) Failure: the trophozoites or cystic form of E. histolytica has persisted for treatment periods, with some intestinal troubles. Methods of treatment and parasitologic examination In each group one third of the patients received 2 capsnles of 250mg. Tiberal thrice daily for 7 days, one third received 2 tablets of 250 mgmetronidazole thrice daily for 7 days, and one third received 2 tablets of 10 mgdehydroemetine thrice daily for 7 days as the only specific drug. No associated drugs were given together for symptomatic relief in all cases. The reason why fixed 7 days dose were delivered to every cases was based on convenience of stool examination and equalizing the number of days for therapy. The therapeutic drugs were delivered usually for 2 days dose (1st prescription), 3 days dose and 2 days dose (3rd prescription) successively, therefore stool examination had been done on 3rd, 6th and 8-10th day of therapy. Clinical results In oligosymptomatic amoebiasis, 20 cases each were treated with doses of 1,500mg/day of Tiberal and metronidozole for 7 days respectively, and 20 cases were treated with doses of 60mg/day of dehydroemetine for 7 days. The total doses administered were 10,5g, 10,5g, and 420mg respectively in a period of 7 days. Among tiberal group 19 cases were found to be negative after therapy whereas there was 1 with parasitological failure. The clinical effect was fast in 95% of the cases. Effective cure was achieved in 17 whereas symptoms persist in 3 patients among 20 cases. There were 1 failure and 2 late relapse. Comparing data of therapeutic results with that of metronidazole and dehydroemetine were shown in Table 2 & 3. Table 3 shows the negativity rate of trophozoits or cystic form of E. histolytica in stools according to therapeutic periods of trial drugs received. The data would indicated that 5 days dose could not be enough to eradicate the parasites even in the susceptible cases. The result data of clinical improvement and clearance of E. histolytica in patient stool among drug trial groups were shown in Table 4. The cases treated with Tiberal showed no clinical signs on average 4,9 days and negative amoeba in stool on average 4,1 days of therapeutic periods, comparing with on average 5,8 days and 4,1 days in metronidazole-treated group, and on average 6,3 days and average 4,5 days in dehydroemetine-treated group respectively. Authors put in order the therapeutic procedures and their result of failed or relapsed cases with unplanned measures in table 5. These data could be obtained after the completion of the comparative double blind study by the code numbers which were publically drawn afterwards. These therapeutic procedures had been made just incidentally, not by prior plan. 2 cases, 4 cases and 3 cases could get finally effective cure by doubling doses of 7 days course of Tiberal, metronidazole and dehydroemetine respectively. 1 failed case treated with dehydroemetine and 1 another failed case with tiberal could get effective cure by additionally receiving metronidazole and dehydroemetine respectively. 2 failed cases treated with metronidazole could be cleared of parasites by adding tiberal effectively. Adverse reactions were noticed in 20% each of the patients treated with Tiberal and also with metronidazole, and 25% of those treated with dehydroemetine. They were all transient and never severe. There was not a single case who was discontinued on therapy owing to its side-effects. No significant change of laboratory data was noticed by the administration of trial drugs. Brief summary Tiberal, metronidazole and dehydroemetine (oral) were all recognized as highly efficacious anti-amoebic drugs in this clinical studies. On account of following standpoints 1) clearance of parasites in stool 2) clinical symptomatic relieving 3) drug tolerance 4) rate of relapse and failure 5) side-effects, Tiberal could be received much more recognition than metronidazole and dehydroemetine did. P. S. Authors has experienced other 10 cases of amoebiasis among in patients (5 moderate severe intestinal amoebiasis, 4 liver abscesses and 1 lung abscess) treated with Tiberal and metronidazole with excellent therapeutic results, without any sequelae or relapse.
-
-
Chong, Yong Pil,Park, Ki-Ho,Kim, Eun Sil,Kim, Mi-Na,Kim, Sung-Han,Lee, Sang-Oh,Choi, Sang-Ho,Jeong, Jin-Yong,Woo, Jun Hee,Kim, Yang Soo American Society for Microbiology 2015 Antimicrobial Agents and Chemotherapy Vol.59 No.6
<P>The prevalence of the heterogeneous vancomycin-intermediate <I>Staphylococcus aureus</I> (hVISA) phenotype among methicillin-resistant <I>S. aureus</I> (MRSA) blood isolates can reach 38%. hVISA bacteremia is known to be associated with vancomycin treatment failure, including persistent bacteremia. We conducted this study to evaluate risk factors for 12-week mortality in patients with hVISA bacteremia through a detailed clinical and microbiological analysis of a prospective cohort of patients with <I>S. aureus</I> bacteremia. All isolates were collected on the first day of bacteremia and subjected to population analysis profiling for hVISA detection, genotyping, and PCR analysis for 39 virulence factors. Of 382 patient with MRSA bacteremia, 121 (32%) had hVISA bacteremia. Deceased patients were more likely to have hematologic malignancy (<I>P</I> = 0.033), ultimately or rapidly fatal disease (<I>P</I> = 0.007), and a higher Pitt bacteremia score (<I>P</I> = 0.010) than surviving patients. The sequence type 239 (ST239) clonal type and definitive linezolid treatment were associated with a trend toward reduced mortality (<I>P</I> = 0.061 and 0.072, respectively), but a high vancomycin MIC (≥2 mg/liter) was not associated with increased mortality (<I>P</I> = 0.368). In a multivariate analysis, ultimately or rapidly fatal disease (adjusted odds ratio [aOR], 2.80; 95% confidence interval [CI], 1.14 to 6.85) and a high Pitt bacteremia score (aOR, 1.26; 95% CI, 1.07 to 1.48) were independent risk factors for mortality. Hematologic malignancy was associated with a trend toward increased mortality (<I>P</I> = 0.094), and ST239 was associated with a trend toward reduced mortality (<I>P</I> = 0.095). Our study suggests that ST239 hVISA is a possible predictor of survival in hVISA bacteremia.</P>
-
Chong, Yong Pil,Lee, Sang-Oh,Song, Eun Hee,Lee, Eun Jung,Jang, Eun-Young,Kim, Sung-Han,Choi, Sang-Ho,Kim, Mi-Na,Jeong, Jin-Yong,Woo, Jun Hee,Kim, Yang Soo Scandinavian University Press [etc.] 2010 Scandinavian journal of infectious diseases Vol.42 No.6
<P>Quinupristin-dalfopristin and linezolid are widely used for the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections. Increasing resistance of VREF to quinupristin-dalfopristin and linezolid is a cause for concern. To determine the efficacy of and the rate of development of resistance to quinupristin-dalfopristin and linezolid, we analyzed all episodes of clinically significant VREF bacteraemia at a tertiary-care hospital from January 2003 to June 2007. The main outcomes were rates of 30-day mortality, microbiological response, and development of resistance. Fifty-two patients were treated with quinupristin-dalfopristin and 61 were treated with linezolid. Baseline demographic and clinical characteristics were similar between the 2 groups. There were no significant between-group differences in 30-day mortality (48% in the quinupristin-dalfopristin group vs 41% in the linezolid group; p = 0.45) or microbiological response (60% vs 66%; p = 0.51). However, prolonged bacteraemia (18% of 45 evaluable cases vs 4% of 55 evaluable cases; p = 0.04) and development of resistance in blood isolates (11% vs 0%; p = 0.02) were more frequently observed in the quinupristin-dalfopristin group than in the linezolid group. There was no significant difference between the efficacy of quinupristin-dalfopristin and linezolid. However, prolonged bacteraemia and the development of resistance were more common in quinupristin-dalfopristin-treated patients.</P>
-
-
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
